UGM & Conference in North America

Discovery and profiling of novel, intestinally-restricted oral pan-JAK inhibitors for the treatment of inflammatory bowel diseases

Jennifer Kozak
Research Scientist, Theravance
(THURSDAY, June 22 - Scientific Presentations, 16:30-17:00)

There remains a significant need for improved therapies to treat inflammatory bowel diseases, including ulcerative colitis (UC). The oral JAK inhibitor tofacitinib has demonstrated clinical effectiveness in treating UC patients in Phase 3 trials, although its usage may be limited by adverse events resulting from systemic drug levels. Here we report the structure-based design and profiling of a series of novel, pan-JAK inhibitors designed to be intestinally-restricted thereby minimizing systemic side effects.